FDA Panel Points to Narrower Label for Amgen's (AMGN) Repatha, Nomura Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cowen Maintains Bullish View on Amgen (AMGN) Following Panel Repatha In Familial Hypercholesterolemia
June 11, 2015 7:13 AM EDTCowen analyst Eric Schmidt reiterating an Outperform rating and $189 price target on Amgen (NASDAQ: AMGN) after an FDA panel backed Repatha in familial hypercholesterolemia.
Analyst Erich Schmidt commented, "The FDA's EMDAC panel recommended Repatha be approved for HoFH (15:0 vote) and one more additional very... More
Amgen (AMGN) Bullish Stance Reiterated at Jefferies Following Repatha Panel Backing
June 11, 2015 6:43 AM EDTJefferies analyst Eun Yang reiterated a Buy rating and $195 price target on Amgen (NASDAQ: AMGN) after an FDA panel recommended approval of Repatha, as expected.
Yang commented, "Positive panel votes were widely expected (11-4 in favor for non-HoFH high-risk pts;... More
After-Hours Stock Movers 06/10: (BOX) (KKD) (MW) Higher; (DRNA) (FOLD) (BBG) Lower (more...)
June 10, 2015 6:01 PM EDTBox (NYSE: BOX) 8.7% HIGHER; reported Q1 EPS of ($0.28), $0.03 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $63.7 million. Q2 revenue is expected to be in the range of $69 to $70 million, versus the consensus of $67 million. FY16 revenue is expected to be in the range of $286 to $290 million, compared to previous guidance of $281 to $285 million and the consensus of $283 million.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) 5.5% LOWER; Alnylam Pharma... More
UPDATE: Amgen (AMGN) Wins FDA Panel Backing for Repatha
June 10, 2015 3:57 PM EDT(Updated - June 10, 2015 4:26 PM EDT)
An FDA panel voted 11-4 to back Amgen's (NASDAQ: AMGN) Repatha in some patients. The panel also backed the drug for HoFH with a vote of 15-0.
Repatha is an investigational fully human monoclonal antibody that inhibits... More
